---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-001770"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T17:52:51.250076+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cyclacel acquires Plogosertib assets from liquidated subsidiary for £250K

## Summary
- Cyclacel Pharmaceuticals buys PLK1 inhibitor Plogosertib assets from wholly-owned UK subsidiary in liquidation for £250,000.
- Includes patent rights, API, CMC data, preclinical and clinical data, and know-how related to Plogosertib.
- Buyer agrees to only sell assets for cash consideration within 24 months; any surplus (50% of net proceeds) paid to subsidiary.
- Transaction closed on March 10, 2025; Patent Assignment Agreement also executed.
- Debt/liabilities of seller not assumed; buyer responsible for subsequent disposal surplus payments.

## SEC filing metadata
- accession: 0001829126-25-001770
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000182912625001770/0001829126-25-001770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000182912625001770/cyclacel_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-001770
- JSON: https://secwatch.observer/filing/0001829126-25-001770.json
- Plain text: https://secwatch.observer/filing/0001829126-25-001770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.